Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Chromatography in Pharmaceuticals and Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for ...

A $2 billion biotech deal has one investor salivating at the prospect of more lucrative M&A deals in the sector as global ...

Vertex currently generates most of its revenue from its drugs that treat cystic fibrosis (CF), a rare disease that causes ...

December 2025 marked an exceptionally active period for life sciences regulation in the European Union (EU). Within the space of a few days, EU institutions have reached political agreement on the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The biotech industry is primed for increased M&A activity due to low valuations and big pharma's need to offset patent losses. Mirum Pharmaceuticals, with three approved drugs and a strong pipeline, ...

Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...

TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies LAS VEGAS--(BUSINESS ...

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive ...

The drugmaker should significantly mitigate its most important risk as it develops new products.